Liquidia Co. (NASDAQ:LQDA) Shares Bought by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP raised its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 104.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,770 shares of the company's stock after purchasing an additional 31,027 shares during the quarter. ExodusPoint Capital Management LP owned 0.07% of Liquidia worth $715,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Rangeley Capital LLC purchased a new stake in Liquidia in the fourth quarter valued at $2,246,000. Cinctive Capital Management LP boosted its stake in shares of Liquidia by 38.5% in the fourth quarter. Cinctive Capital Management LP now owns 61,528 shares of the company's stock worth $724,000 after buying an additional 17,112 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Liquidia in the fourth quarter worth about $220,000. Geode Capital Management LLC grew its holdings in Liquidia by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after acquiring an additional 101,597 shares during the period. Finally, Diametric Capital LP raised its position in Liquidia by 6.2% during the fourth quarter. Diametric Capital LP now owns 132,028 shares of the company's stock valued at $1,553,000 after acquiring an additional 7,696 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the transaction, the insider now owns 267,943 shares of the company's stock, valued at $3,483,259. This trade represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 30.10% of the company's stock.

Remove Ads

Liquidia Price Performance

LQDA stock traded down $0.23 during trading on Tuesday, hitting $13.60. The stock had a trading volume of 697,219 shares, compared to its average volume of 965,944. The company's 50-day moving average price is $14.84 and its two-hundred day moving average price is $12.72. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The stock has a market capitalization of $1.16 billion, a P/E ratio of -8.34 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, sell-side analysts expect that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LQDA shares. Wells Fargo & Company started coverage on Liquidia in a research report on Friday, December 20th. They issued an "overweight" rating and a $20.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and set a $25.00 price target on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).